Overview
Prospective controlled studies to identify clinical epilepsy control, cognitive changes, and safety in VNS treatment of tuberculosis-related epilepsy.
Description
Control group: no clear epilepsy focus in the brain, and medication has been continued.
Surgery group: no clear epilepsy focus in the brain, and VNS for tuberculosis-related epilepsy.
In order to ensure the follow-up of the study and 3 years after the end of the study, 50 cases were collected in each group of the study.
Eligibility
Inclusion Criteria:
- 2 years old and above, no gender restriction, TSC gene monitoring with or without abnormality
- Diagnosis of nodular sclerosis and epilepsy
- Epilepsy course for more than 1 year
- Patients who have taken 3 or more reasonable choices with appropriate and tolerable antiepileptic drugs (excluding mTOR inhibitors and traditional Chinese medicine and prescriptions) had seizures more than 12 times in the 3 months before enrollment
- The family members agreed to enroll and signed the informed consent.
Exclusion Criteria:
- Obvious renal angiomyolipoma, pulmonary lymphoma leiomyomatosis, and subventricular giant cell astrocytoma
- Abnormal heart, lung, liver, and kidney functions and coagulation function
- The family did not sign the informed consent
- Preoperative evaluation, it is considered that no surgical treatment is needed
- The patient received other craniocerebral surgical treatment within 1 year during the follow-up period